TITLE

No Strings Attached

AUTHOR(S)
Peters, Rita C.
PUB. DATE
May 2012
SOURCE
Drug Discovery & Development;May2012, Vol. 15 Issue 5, p4
SOURCE TYPE
Periodical
DOC. TYPE
Editorial
ABSTRACT
The author discusses the implications of the reauthorization of the Prescription Drug User Fee Act (PDUFA) in the U.S. She explains that the legislation must be renewed before its expiration date on September 30, 2012 because it may compromise the drug review process and may force the Food and Drug Administration (FDA) to lay off as many as 2,000 employees. She also cites a report of the Tufts Center on the mixed regulatory burden presented by PDUFA to drug sponsors.
ACCESSION #
79324338

 

Related Articles

  • The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context. Royall, M. Sean; Lipton, Joshua // Antitrust Magazine;Spring2010, Vol. 24 Issue 2, p22 

    The article focuses on the complexities involved in litigating generic drug exclusion claims made by the branded pharmaceutical manufacturers under the U.S. antitrust law. It discusses the Hatch-Waxman Act which permits a generic manufacturer to file an Abbreviated New Drug Application, to be...

  • FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes. Kesselheim, AS; Darrow, JJ // Clinical Pharmacology & Therapeutics;Jan2015, Vol. 97 Issue 1, p29 

    New prescription drugs receive approval from the US Food and Drug Administration (FDA) based on tests establishing safety and adequate and well-controlled trials demonstrating 'substantial evidence' of efficacy. However, a number of legislative and regulatory initiatives, the most recent being...

  • Eliminating the U.S. drug lag: Implications for drug safety. Olson, Mary // Journal of Risk & Uncertainty;Aug2013, Vol. 47 Issue 1, p1 

    An increase in new drugs first launched in the U.S. and shorter lags between first global drug launch and U.S. approval indicate that the U.S. drug lag has declined. This paper examines the impact of these changes on drug safety using adverse drug reaction data for FDA-approved drugs in 1990 to...

  • Hurdles Ahead for 'Cures' Legislation, PDUFA Renewal. WECHSLER, JILL // Pharmaceutical Executive;Aug2015, Vol. 35 Issue 8, p10 

    The article focuses on the hurdles against the 21st Century Cures Act from the U.S. Senate despite its approval from the House of Representatives. Topics discussed include the Food and Drug Administration's launch of the Prescription Drug User Fee Act (PDUFA), the user reauthorization process,...

  • Trouble at the office. Allison, Malorye // Nature Biotechnology;Sep2008, Vol. 26 Issue 9, p967 

    The article discusses an investigation into the role of surrogate endpoints used in the approval of drugs by the U.S. Food and Drug Administration's (FDA) Office of Oncology Drug Products (OODP). An example is given of cancer treatment drugs, such as Avastis used in the treatment of breast...

  • New drug and biological product approvals, 2010. Traynor, Kate // American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p186 

    The article presents the drugs which received the marketing approval from the U.S. Food & Drug Administration (FDA). It includes the Tocilizumab or Actemra which is used for treating moderate to severe rheumatoid arthritis, the Pradaxa oral thrombin inhibitor, and the tesamorelin or Egrifta for...

  • 2010 Pharmaceutical Approvals.  // American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p188 

    The article presents the 2010 approved drugs in the U.S. It includes the Alcaftadine ophthalmic solution treatment for allergic conjunctivitis, the Carglumic acid tablets use for treating acute hyperammonemia caused by the deficiency of N-acetylglutamate synthase (NAGS), and Dabigatran etexilate...

  • The Food and Drug Administration Amendments Act and Postmarketing Commitments. Fain, Kevin; Daubresse, Matthew; Alexander, G. Caleb // JAMA: Journal of the American Medical Association;7/10/2013, Vol. 310 Issue 2, p202 

    The article focuses on a study which examined the changes associated with post-marketing studies that are required for a prescription drug's approval and adherence by the U.S. Food and Drug Administration (FDA) as per the Food and Drug Administration Amendments Act (FDAAA) of 2007. It further...

  • In Opposition to Liberty: We Need a “Sovereign” to Govern Drug Claims. Avorn, Jerry // Annals of Internal Medicine;8/4/2015, Vol. 163 Issue 3, p229 

    The author comments on the plans of the U.S. Food and Drug Administration (FDA) to hold a public meeting to discuss whether its restrictions on drug manufacturers' claim about their products infringes their liberty. Topics discussed include need for FDA to allow companies to review the available...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics